All updated as on -
In 2022, the market for lipid nanoparticles was estimated to be worth USD 687.15 million. A 14.6% CAGR is predicted for the market during the projection period as it rises from USD 777.14 million in 2023 to USD 1,895.10 million in 2030. The COVID-19 pandemic has had an unprecedented and overwhelming impact on the world, and demand for lipid nanoparticles has increased more than was predicted in all regions compared to pre-pandemic levels.
The market experienced rapid revenue growth in 2020 as a result of the growing use of these goods as vaccine delivery vehicles. Since lipid nanoparticles transport gene-based vaccines to the proper target site in the human body, they are crucial for the delivery of fragile m-RNA used in COVID-19 vaccines into cells. As a result, the use of LNPs in COVID-19 vaccines has increased. For instance, LNPs are used by Pfizer Inc. and Moderna Inc. to create mRNA COVID-19 vaccines.
The market participants noticed a large increase in revenue during 2020. For instance, Merck KGaA reported an increase in sales income from these nanoparticles of about 9.5% in 2020 compared to 2019. Additionally, Croda International Plc. signed a five-year contract in 2020 to provide lipid components for the Pfizer-BioNTech COVID-19 vaccine. Critical Croda components were included in the COVID-19 vaccine that was given to 25.0 million people, enabling the business to help Pfizer-BioNTech reach its goal of distributing 50.0 million doses of the COVID-19 vaccine.
One of the key factors that is anticipated to influence demand for goods like pharmaceuticals & healthcare, dietary supplements, functional food, functional beverages, cosmetic & personal care, and more is the rapid increase in population in regions like Asia Pacific, Europe, and North America. The main element for its significant use in food and beverage goods is the high amount of omega 3 and omega 6 in lipids.
Additionally, the increasing cost of fatty acids and other raw ingredients on a global scale hinders market expansion. These pricing changes are a result of COVID-19's effects and the current geopolitical strife in Europe. Fatty acid prices in North America changed in the first quarter of 2022 due to a drop in demand from the personal care, cosmetics, and food industries. Additionally, supply limitations from Asian nations had to be faced by American producers of fatty acids.
The growing need for RNA-based therapeutics, notably for the treatment of cancer and genetic disorders, is propelling the global lipid nanoparticles (LNP) market. Effective therapy options now include RNA-based treatments like messenger RNA (mRNA) and small interfering RNA (siRNA), which can target particular genes and proteins linked to diseases. Because they can prevent RNA from being broken down in the body and aid in helping it reach its intended target cells, LNPs are actively being developed as a delivery strategy for RNA-based therapeutics. This has led to a significant increase in the amount of research and development being done in the area of LNP-based medication delivery. Therefore, it is anticipated that the LNP market will continue to expand in the years to come as a result of the growing need for RNA-based therapeutics.
In gene therapy, lipid nanoparticles are used as vectors to cure genetic problems. Unlike viral proteins, these are less dangerous. They can transport nucleic acids of different sizes to cells. Additionally, they can be made fast by combining different targeted ligands. The leading businesses' strong focus on mergers and acquisitions to build new production facilities is also accelerating the use of LNP products.
Report Coverage
Global Lipid Nanoparticles research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Lipid Nanoparticles report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Lipid Nanoparticles competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Lipid Nanoparticles market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Lipid Nanoparticles market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Lipid Nanoparticles market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Merck KGaA, Evonik Industries AG, Gattefosse, Precision NanoSystems, IOI Oleo GmbH, Genevant Sciences, Exelead, Avanti Polar Lipids, Nippon Fine Chemicals Co. Ltd., Lipoid GmbH, Cargill, Incorporated, BASF SE, Archer Daniels Midland Company, Koninklijke DSM N.V., Kerry Group plc, Nordic Naturals, Inc., Clover Corporation, Croda International plc, Lipoid Kosmetik AG, Omega Protein Corporation.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Lipid Nanoparticles market based on the below-mentioned segments:
Global Lipid Nanoparticles Market, By Type
Solid Lipid Nanoparticles (SLNs)
Nanostructured Lipid Carriers (NLCs)
Others
Global Lipid Nanoparticles market, By Application
Therapeutics
Research
Global Lipid Nanoparticles Market, By End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Global Lipid Nanoparticles market, Regional Analysis
The market experienced rapid revenue growth in 2020 as a result of the growing use of these goods as vaccine delivery vehicles. Since lipid nanoparticles transport gene-based vaccines to the proper target site in the human body, they are crucial for the delivery of fragile m-RNA used in COVID-19 vaccines into cells. As a result, the use of LNPs in COVID-19 vaccines has increased. For instance, LNPs are used by Pfizer Inc. and Moderna Inc. to create mRNA COVID-19 vaccines.
The market participants noticed a large increase in revenue during 2020. For instance, Merck KGaA reported an increase in sales income from these nanoparticles of about 9.5% in 2020 compared to 2019. Additionally, Croda International Plc. signed a five-year contract in 2020 to provide lipid components for the Pfizer-BioNTech COVID-19 vaccine. Critical Croda components were included in the COVID-19 vaccine that was given to 25.0 million people, enabling the business to help Pfizer-BioNTech reach its goal of distributing 50.0 million doses of the COVID-19 vaccine.
One of the key factors that is anticipated to influence demand for goods like pharmaceuticals & healthcare, dietary supplements, functional food, functional beverages, cosmetic & personal care, and more is the rapid increase in population in regions like Asia Pacific, Europe, and North America. The main element for its significant use in food and beverage goods is the high amount of omega 3 and omega 6 in lipids.
Additionally, the increasing cost of fatty acids and other raw ingredients on a global scale hinders market expansion. These pricing changes are a result of COVID-19's effects and the current geopolitical strife in Europe. Fatty acid prices in North America changed in the first quarter of 2022 due to a drop in demand from the personal care, cosmetics, and food industries. Additionally, supply limitations from Asian nations had to be faced by American producers of fatty acids.
The growing need for RNA-based therapeutics, notably for the treatment of cancer and genetic disorders, is propelling the global lipid nanoparticles (LNP) market. Effective therapy options now include RNA-based treatments like messenger RNA (mRNA) and small interfering RNA (siRNA), which can target particular genes and proteins linked to diseases. Because they can prevent RNA from being broken down in the body and aid in helping it reach its intended target cells, LNPs are actively being developed as a delivery strategy for RNA-based therapeutics. This has led to a significant increase in the amount of research and development being done in the area of LNP-based medication delivery. Therefore, it is anticipated that the LNP market will continue to expand in the years to come as a result of the growing need for RNA-based therapeutics.
In gene therapy, lipid nanoparticles are used as vectors to cure genetic problems. Unlike viral proteins, these are less dangerous. They can transport nucleic acids of different sizes to cells. Additionally, they can be made fast by combining different targeted ligands. The leading businesses' strong focus on mergers and acquisitions to build new production facilities is also accelerating the use of LNP products.
Report Coverage
Global Lipid Nanoparticles research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Lipid Nanoparticles report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Lipid Nanoparticles competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Lipid Nanoparticles market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Merck KGaA, Evonik Industries AG, Gattefosse, Precision NanoSystems, IOI Oleo GmbH, Genevant Sciences, Exelead, Avanti Polar Lipids, Nippon Fine Chemicals Co. Ltd., Lipoid GmbH, Cargill, Incorporated, BASF SE, Archer Daniels Midland Company, Koninklijke DSM N.V., Kerry Group plc, Nordic Naturals, Inc., Clover Corporation, Croda International plc, Lipoid Kosmetik AG, Omega Protein Corporation. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Lipid Nanoparticles Market from 2021 to 2030.
- Market Forecast for Lipid Nanoparticles Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Lipid Nanoparticles competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Lipid Nanoparticles
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Lipid Nanoparticles market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Lipid Nanoparticles market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Merck KGaA, Evonik Industries AG, Gattefosse, Precision NanoSystems, IOI Oleo GmbH, Genevant Sciences, Exelead, Avanti Polar Lipids, Nippon Fine Chemicals Co. Ltd., Lipoid GmbH, Cargill, Incorporated, BASF SE, Archer Daniels Midland Company, Koninklijke DSM N.V., Kerry Group plc, Nordic Naturals, Inc., Clover Corporation, Croda International plc, Lipoid Kosmetik AG, Omega Protein Corporation.
Primary Target Market
- Market Players of Lipid Nanoparticles
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Lipid Nanoparticles market based on the below-mentioned segments:
Global Lipid Nanoparticles Market, By Type
Solid Lipid Nanoparticles (SLNs)
Nanostructured Lipid Carriers (NLCs)
Others
Global Lipid Nanoparticles market, By Application
Therapeutics
Research
Global Lipid Nanoparticles Market, By End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Global Lipid Nanoparticles market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive lipid nanoparticles market market research and competitor analysis for your business to help you develop more profound insights into the lipid nanoparticles market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the lipid nanoparticles market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.